

# Clinical trials of All mechanism for obesity and overweight in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 Bupropion

Trial	Treatments	Patients	Trials design and methods
<b>Bupropion vs placebo</b>			
<b>Anderson , 2002</b> n=105/112 follow-up: 24 weeks	bupropion SR 300, or 400 mg/d. versus placebo	obese adults	double-blind
<b>Croft , 2002</b> n=210/213 follow-up: 44 weeks	Bupropion, 300 mg for 44 wk versus Placebo	patients with major depression responder to open-label treatment with bupropion SR	double-blind
<b>Jain , 2002</b> n=213/209 follow-up: 26 weeks	bupropion SR 300 mg/d versus Placebo	Obese adults (body mass index, 30 to 44 kg/m <sup>2</sup> ) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30)	double-blind

## References

### Anderson, 2002:

Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. *Obes Res* 2002 Jul;10:633-41 [[12105285](#)]

### Croft, 2002:

Croft H, Houser TL, Jamerson BD, Leadbetter R, Bolden-Watson C, Donahue R, Metz A Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. *Clin Ther* 2002 Apr;24:662-72 [[12017410](#)]

### Jain, 2002:

Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. *Obes Res* 2002 Oct;10:1049-56 [[12376586](#)]

## 2 Fluoxetine

Trial	Treatments	Patients	Trials design and methods
<b>Fluoxetine vs placebo</b>			
<b>Breum , 1995</b> n=20/20 follow-up:	Fluoxetine, 60 mgfor 52 wk versus Placebo	aaaa	

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>Connolly , 1995</b> n=15/15 follow-up:	fluoxetine 60 mg daily versus placebo	obese elderly patients over 60 years of age with Type 2 diabetes	double-blind
<b>Darga , 1991</b> n=23/22 follow-up: 52 weeks	fluoxetine versus placebo	obese subjects	
<b>Goldstein , 1994</b> n=182/184 follow-up: 52-week	Fluoxetine, 60 mgfor 52 wk versus Placebo	obese outpatients	double-blind
<b>Gray , 1992</b> n=24/24 follow-up: 24 weeks	Fluoxetine, 60 mg for 6 mo versus Placebo	obese, type 2 non-insulin dependent diabetics being treated with insulin	double blind
<b>Marcus , 1990</b> n=23/22 follow-up:	Fluoxetine, 60 mgfor 52 wk versus Placebo	-	
<b>Mendoza Espejo , 1995</b> n=0/30 follow-up:	Fluoxetine, 180 mgfor 6 mo versus Placebo	-	
<b>Michelson 50wk , 1999</b> n=102/102 follow-up:	Fluoxetine, 20 mgfor 50 wk versus Placebo	-	
<b>OKane , 1994</b> n=10/10 follow-up:	-	-	

2

## References

### **Breum, 1995:**

Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. *Metabolism* 1995 Dec;44:1570-6 [8786726]

### **Connolly, 1995:**

Connolly VM, Gallagher A, Kesson CM A study of fluoxetine in obese elderly patients with type 2 diabetes. *Diabet Med* 1995 May;12:416-8 [7648804]

### **Darga, 1991:**

Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP Fluoxetine's effect on weight loss in obese subjects. *Am J Clin Nutr* 1991 Aug;54:321-5 [1858696]

### **Goldstein, 1994:**

Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR Fluoxetine: a randomized clinical trial in the treatment of obesity. *Int J Obes Relat Metab Disord* 1994 Mar;18:129-35 [8186809]

### **Gray, 1992:**

Gray DS, Fujioka K, Devine W, Bray GA Fluoxetine treatment of the obese diabetic. *Int J Obes Relat Metab Disord* 1992 Mar;16:193-8 [1317828]

### **Marcus, 1990:**

Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. *Am J Psychiatry* 1990 Jul;147:876-81 [2192563]

### **Mendoza Espejo, 1995:**

Mendoza Espejo R, Diaz Perez de Madrid J, Buitrago F [Effectiveness of serotonergic agonists in the treatment of obese patients] *Aten Primaria* 1995 Oct 15;16:364-6 [7488690]

### Michelson 50wk, 1999:

Michelson D, Amsterdam JD, Kim Y, Sundell K. nten Changes in weight during a one-year trial with fluoxetine [Abstract] 152nd Annual Meeting of

### OKane, 1994:

O'Kane M, Wiles PG, Wales JK Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994 Jan-Feb;11:105-10 [8181239]

## 3 glucagon-like peptide-1

Trial	Treatments	Patients	Trials design and methods
<b>liraglutide vs placebo</b>			
<b>Astrup (NN8022-1807 ) , 2009</b> [NCT00422058] n=NA follow-up: 20 weeks	4 liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg daily) versus placebo	obese individuals without type 2 diabetes	Parallel groups double blind Europe

## References

### Astrup (NN8022-1807 ) , 2009:

Astrup A, Rssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009 Oct 22;: [19853906] 10.1016/S0140-6736(09)61375-1

## 4 lipase inhibitor

Trial	Treatments	Patients	Trials design and methods
<b>Orlistat vs placebo</b>			
<b>Bakris , 2002</b> n=278/276 follow-up: 1-year	orlistat versus placebo	obese individuals with inadequately controlled hypertension.	double-blind
<b>Broom , 2002</b> n=265/261 follow-up: 54-week	orlistat versus placebo	obese patients with cardiovascular risk	parallel group double-blind
<b>Broom, , 2001</b> n=71/71 follow-up:	-	-	
<b>Davidson , 1999</b> n=668/224 follow-up: 52 weeks	orlistat, 120 mg 3 times a day, for 52 weeks versus placebo	Obese adults (BMI 30-43 kg/m2)	double-blind US
<b>Deerochanawong, , 2001</b> n=126/126 follow-up:	-	-	

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Derosa , 2003 n=27/23 follow-up: 1-year	orlistat 120 mg TID versus placebo	obese patients with hypercholesterolemia	double-blind
Gotfredsen , 2001 n=16/14 follow-up:	-	-	
Halpern , 2003 n=169/174 follow-up: 24 weeks	orlistat (120 mg t.i.d.), versus placebo	Obese, non-insulin-dependent diabetic patients, aged 18-70 years old, with BMI >27 kg/m <sup>2</sup>	parallel Double-blind Latin-America
Hanefeld , 2002 n=195/188 follow-up: 48-week	orlistat 120 mg t.i.d. versus placebo	Overweight or obese adults (BMI ≥ 28 kg/m <sup>2</sup> ) with HbA1c of 6.5-11% and clinical type 2 diabetes	double-blind
Hauptman , 2000 n=210/212 follow-up: 1 year	60 mg of orlistat TID or 120 mg of orlistat TID, versus placebo	obese patients (BMI 30-44 kg/m <sup>2</sup> )	double-blind USA
Hill , 1999 n=181/188 follow-up: 1 year	30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y versus placebo	Obese subjects who lost ≥ 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy	double-blind
Hollander , 1998 n=163/159 follow-up: 57-week	120 mg orlistat orally three times a day versus placebo	obese men and women with type 2 diabetes who were aged >18 years, had a BMI of 28-40 kg/m <sup>2</sup> , and were clinically stable on oral sulfonylureas	double-blind
Karhunen , 2000 n=36/36 follow-up: 1 y.	orlistat 120 mg t.i.d. versus placebo	obese subjects	double-blind
Kelley , 2002 n=274/276 follow-up: 1-year	orlistat 120 mg three times a day versus placebo	overweight or obese adults (BMI 28-40 kg/m <sup>2</sup> ) with type 2 diabetes treated with insulin alone or combined with oral agents, but with suboptimal metabolic control (HbA(1c) 7.5-12.0% )	double-blind
Krempf , 2005 n=346/350 follow-up: 18-month	orlistat 120 mg three times daily versus placebo	otherwise healthy, overweight patients aged 18-65 y (BMI ≥28 kg/m <sup>2</sup> )	double-blind
Lindgarde , 2000 n=190/186 follow-up: 1 year	orlistat 120 mg three times daily versus placebo	obese adults (body mass index 28-38 kg m-2) with type 2 diabetes, hypercholesterolaemia and/or hypertension	double-blind Sweden
Lucas , 2003 n=256/188 follow-up:	-	-	
Micic , 1999 n=60/59 follow-up: 24 weeks	orlistat 120 mg three times daily versus placebo	obese patients (BMI ≥ 30 kg/m <sup>2</sup> ) with hyperlipidemia (LDL-cholesterol ≥ 4, 2 mmol/l)	double-blind

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Miles , 2002 n=255/261 follow-up: 1 year	120 mg orlistat t.i.d. versus placebo	overweight and obese patients with suboptimal control of type 2 diabetes	double-blind
Muls , 2001 n=147/147 follow-up: 24 week	orlistat 120 mg three times daily versus placebo	obese hypercholesterolemic patients, BMI between 27-40 kg/m2 and low-density-lipoprotein cholesterol, LDL-C, between 4.1-6.7 mmol/l	double-blind
Naumov , 2002 n=15/15 follow-up:	orlistat versus diet alone	patients with stable angina pectoris concomitant with obesity and hyperlipemia	open
Reaven , 2001 n=156/91 follow-up:	-	-	
Rissanen , 2001 n=25/26 follow-up: 12-month	orlistat 120 mg three times daily versus placebo	healthy obese women	double-blind
Rosenfalck , 2002 n=3/1 follow-up:	-	obese patients	
Rossner , 2000 n=244/243 follow-up: 2-year	orlistat (60 or 120 mg) three times a day versus Obese patients (body mass index 28 to 43 kg/m2)	Obese patients (body mass index 28 to 43 kg/m2)	double-blind
Shi Yi , 2001 n=986/142 follow-up:	-	-	
Sjostrom , 1998 n=345/343 follow-up: 1 year	-	-	double-blind Europe
Vidgren , 1999 n=37/38 follow-up: 1 year	120 mg of orlistat three times a day versus placebo	obese subjects	

## References

### Bakris, 2002:

Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 Nov;20:2257-67 [12409965]

### Broom, 2002:

Broom I, Wilding J, Stott P, Myers N Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002 Sep;56:494-9 [12296610]

### Broom,, 2001:

Broom I. Randomised trial of the effect of orlistat on body weight and CVD risk profile in overweight and obese patients with co-morbidities [Abstract]. Int J Obes. 2001;25 Suppl:S106

### Davidson, 1999:

Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. *JAMA* 1999 Jan 20;281:235-42 [[9918478](#)]

**Deerochanawong,, 2001:**

Deerochanawong C. Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [Abstract]. *Diabetes*. 2001;50:A433.

**Derosa, 2003:**

Derosa G, Mugellini A, Ciccarelli L, Fogari R Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. *Clin Ther* 2003 Apr;25:1107-22 [[12809960](#)]

**Gotfredsen, 2001:**

Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. *Am J Cardiol* 2001 Apr 1;87:827-31 [[11274935](#)]

**Halpern, 2003:**

Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. *Diabetes Obes Metab* 2003 May;5:180-8 [[12681025](#)]

**Hanefeld, 2002:**

Hanefeld M, Sachse G The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. *Diabetes Obes Metab* 2002 Nov;4:415-23 [[12406041](#)]

**Hauptman, 2000:**

Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR Orlistat in the long-term treatment of obesity in primary care settings. *Arch Fam Med* 2000 Feb;9:160-7 [[10693734](#)]

**Hill, 1999:**

Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. *Am J Clin Nutr* 1999 Jun;69:1108-16 [[10357727](#)]

**Hollander, 1998:**

Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. *Diabetes Care* 1998 Aug;21:1288-94 [[9702435](#)]

**Karhunen, 2000:**

Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, Uusitupa M Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. *Int J Obes Relat Metab Disord* 2000 Dec;24:1567-72 [[11126207](#)]

**Kelley, 2002:**

Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. *Diabetes Care* 2002 Jun;25:1033-41 [[12032111](#)]

**Krempf, 2005:**

Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. *Int J Obes Relat Metab Disord* 2003 May;27:591-7 [[12704403](#)]

**Lindgarde, 2000:**

Lindgarde F The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. *J Intern Med* 2000 Sep;248:245-54 [[10971792](#)]

**Lucas, 2003:**

Lucas CP, Boldrin MN, Reaven GM Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. *Am J Cardiol* 2003 Apr 15;91:961-4 [[12686336](#)]

**Micic, 1999:**

Micic D, Ivkovic-Lazar T, Dragojevic R, Jorga J, Stokic E, Hajdukovic Z Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Med Pregl 1999 Sep-Oct;52:323-33 [10624380]

**Miles, 2002:**

Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 Jul;25:1123-8 [12087008]

**Muls, 2001:**

Muls E, Kolanowski J, Scheen A, Van Gaal L The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001 Nov;25:1713-21 [11753595]

**Naumov, 2002:**

Naumov VG, Lupanov VP, Dotsenko IuV, Tvorogova MG [Six-month xenical (orlistat) therapy of patients with stable angina pectoris concomitant with obesity and hyperlipidemia] Ter Arkh 2002;74:47-51 [11878059]

**Reaven, 2001:**

Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001 Apr 1;87:827-31 [11274935]

**Rissanen, 2001:**

Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001 Feb;25:212-8 [11410822]

**Rosenfalck, 2002:**

Rosenfalck AM, Hendel H, Rasmussen MH, Almdal T, Anderson T, Hilsted J, Madsbad S Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab 2002 Jan;4:19-28 [11890163]

**Rossner, 2000:**

Rossner S, Sjostrom L, Noack R, Meinders AE, Nosedo G Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000 Jan;8:49-61 [10678259]

**Shi Yi, 2001:**

Shi Yi F, Zhu Jun R. Effect of orlistat on weight loss and glycemic control in overweight Chinese patients with type 2 diabetes [Abstract]. Diabetes. 2001;50:A101-A102

**Sjostrom, 1998:**

Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998 Jul 18;352:167-72 [9683204]

**Vidgren, 1999:**

Vidgren HM, Agren JJ, Valve RS, Karhunen LJ, Rissanen AM, Uusitupa MI The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. Clin Pharmacol Ther 1999 Sep;66:315-22 [10511068]

## 5 phentermine and topiramate

Trial	Treatments	Patients	Trials design and methods
PHEN/TPM high dose vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
CONQUER (high-dose) (OB 303) [NCT00553787] n=995/994 follow-up: 56 weeks	PHEN/TPM 15/92 mg versus placebo		
OB 301 (high-dose) <i>unpublished</i> n=108/109 follow-up: 28 weeks	PHEN/TPM 15/92 mg versus placebo		
OB 302 (high-dose) <i>unpublished</i> n=512/514 follow-up: 56 weeks	PHEN/TPM 15/92 mg versus placebo		
<b>PHEN/TPM low-dose vs placebo</b>			
OB 302 (low-dose) <i>unpublished</i> n=241/514 follow-up: 56 weeks	PHEN/TPM 3.75/23 mg versus placebo	-	
<b>PHEN/TPM mid-dose vs placebo</b>			
CONQUER (mid-dose) (OB 303) [NCT00553787] n=498/994 follow-up: 56 weeks	PHEN/TPM 7.5/46 mg versus placebo	-	
OB 301 (mid-dose) <i>unpublished</i> n=107/109 follow-up: 28 weeks	PHEN/TPM 7.5/46 mg versus placebo	-	Parallel groups

## References

### CONQUER (high-dose) (OB 303), 0:

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet* 2011;377:1341-52 [[21481449](#)] [10.1016/S0140-6736\(11\)60205-5](#)

### OB 301 (high-dose), 0:

### OB 302 (high-dose), 0:

### OB 302 (low-dose), 0:

### CONQUER (mid-dose) (OB 303), :

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet* 2011;377:1341-52 [[21481449](#)] [10.1016/S0140-6736\(11\)60205-5](#)

### OB 301 (mid-dose), 0:



## 6 serotonin 5HT<sub>2C</sub>-receptor agonist

Trial	Treatments	Patients	Trials design and methods
<b>lorcaserin vs placebo</b>			
<b>APD356-004 , 2009</b> n=NA follow-up:	-	-	
<b>BLOOM , 2010</b> [NCT00395135] n=NA follow-up: 52 weeks	lorcaserin 10mg bid versus placebo	-	Parallel groups double-blind
<b>BLOOM-DM (10mg bid)</b> <i>unpublished</i> [NCT00603291] n=253/56 follow-up: 52 weeks	lorcaserin 10 mg BID versus placebo	overweight and obese patients with type 2 diabetes mellitus managed with oral hypoglycemic agents	Parallel groups double-blind
<b>BLOSSOM (10mg bid) , 2009</b> [NCT00603902] n=1603/1603 follow-up: 1 year	lorcaserin 10 mg twice daily versus placebo	obese and overweight patients	Parallel groups double blind USA

## References

### APD356-004, 2009:

Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR Lorcaserin (APD356), a selective 5-HT<sub>2C</sub> agonist, reduces body weight in obese men and women. *Obesity* (Silver Spring) 2009;17:494-503 [[19057523](#)] [10.1038/oby.2008.537](#)

### BLOOM, 2010:

Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. *N Engl J Med* 2010 Jul 15;363:245-256 [[20647200](#)] [10.1056/NEJMoa0909809](#)

### BLOOM-DM (10mg bid), :

### BLOSSOM (10mg bid), 2009:

Kaplan LM, Smith SR, Weissman NJ, et al The BLOSSOM trial: efficacy and safety of lorcaserin in obese and overweight men and women *Obesity* 2009; October 27, 2009; Washington, DC

Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. *J Clin Endocrinol Metab* 2011;96:3067-77 [[21795446](#)] [10.1210/jc.2011-1256](#)

## 7 serotonin-norepinephrine reuptake inhibitor

Trial	Treatments	Patients	Trials design and methods
<b>Sibutramine vs placebo</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>SCOUT , 2010</b> [NCT00234832] n=4906/4898 follow-up: 3.4 year	sibutramine versus placebo	overweight or obese patients with diabetes or a history of coronary or peripheral vascular disease or stroke, along with other CV risk factors	Parallel groups double blind
<b>McMahon , 2002</b> n=145/72 follow-up:	-	-	
<b>McMahon , 2000</b> n=142/157 follow-up:	-	-	
<b>Smith , 2001</b> n=142/69 follow-up:	-	-	

## References

### SCOUT, 2010:

James W. P. T. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients Eur Heart J Suppl 2005;7:L44-48

Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007 Dec;28:2915-23 [[17595194](#)]

James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010 Sep 2;363:905-17 [[20818901](#)] [10.1056/NEJMoa1003114](#)

### McMahon, 2002:

McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002 Jan;16:5-11 [[11840224](#)]

### McMahon, 2000:

McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000 Jul 24;160:2185-91 [[10904462](#)]

### Smith, 2001:

Smith IG, Goulder MA Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001 Jun;50:505-12 [[11407998](#)]

## 8 tesofensine

Trial	Treatments	Patients	Trials design and methods
<b>tesofensine vs placebo</b>			
<b>Astrup</b> n=NA follow-up:	-	-	

## References

### Astrup, 0:

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13 [[18950853](#)]

## 9 Topiramate

Trial	Treatments	Patients	Trials design and methods
<b>Topiramate vs placebo</b>			
Bray , 2003 n=75/75 follow-up:	-	-	
Caterson , 2003 n=93/97 follow-up:	-	-	
Pudhomme , 2003 n=33/33 follow-up:	-	-	
Rissanen , 2003 n=123/103 follow-up:	-	-	
Stenlof , 2003 n=135/137 follow-up:	-	-	
Tonstad , 2003 n=178/177 follow-up:	-	-	

## References

### Bray, 2003:

Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003 Jun;11:722-33 [[12805393](#)]

### Caterson, 2003:

Caterson I, Astrup A, Zelissen P, Guy-Grand B, Carruba M, Levy B, et al. The long-term effect of topiramate on body weight maintenance after low-calorie diet-induced weight loss in obese subjects [Abstract]. Presented at the 18th International Diabetes Federation Congress, Paris, France, 2429 August 2003.

### Pudhomme, 2003:

### Rissanen, 2003:

### Stenlof, 2003:

### Tonstad, 2003:

Entry terms: enoxaparin, Lovenox, Clexane, acebutolol, Sectral, Monitan, Rhotral, Neptal, spironolactone, Veroshpiron, Verospirone, Spiro-

beta, Spirogamma, Spirolang, Spiro-no-Isis, Spiro-no Isis, Spiro-no-ne, Spiro-spare, Verospiron, Aldactone, Aldactone A, Aquareduct, duraspiron, Espironolactona Alter, Espironolactona Mundogen, Flumach, Frumikal, Jenaspiron, Novo-Spiroton, Novo Spiroton, NovoSpiroton, Practon, Spiro L.U.T., spiro von ct, , alprenolol, amiloride, amiodarone, Amiobeta, Cordarone, Cordarex, Amiodarex, Kordaron, Trangorex, Amiodarona, Amiohexal, Braxan, Corbionax, Ortacrone, Rytmarone, Tachydaron, Aratac, amrinone, apixaban, BMS 562247, BMS562247, BMS-562247, Eliquis, , aspirin, atenolol, beraprost, TRK 100, TRK-100, beraprost sodium, , benazepril, bezafibrate, Befibrat, Beza-Lande, Beza Lande, BezaLande, Beza-Puren, Beza Puren, BezaPuren, Bezabeta, Bezacur, Bezafibrat PB, Bezafisal, Bezalip, Eulitop, Bezamerck, durabezur, BM-15.075, BM 15.075, BM15.075, Cedur, Difaterol, Bfzal, Lipox, Reducterol, Regadrin B, Sklerofibrat, Solibay, Azufibrat, , fluorescent bezafibrate, DNS-X, , bisoprolol, Bisoprolol Hydrochloride, Bisoprolol Methanesulfonate Salt, EMD-33512, EMD 33512, EMD33512, CL-297939, CL 297939, CL297939, Concor, Bisoprolol Fumarate, , bivalirudin, Hirulog-1 Hirulog Angiomax, bucindolol, bucindolol, bucindolol hydrochloride, MJ 13105, , candesartan, candesartan cilexetil, TCV 116, TCV-116, Atacand, Blopress, Kenzen, Amias, Parapres, candesartan, CV 11974, CV11974, CV-11974, , carvedilol, carvedilol, Querto, Coreg, Dilatrend, Kredex, Coropres, Eucardic, BM 14190, BM-14190, cerivastatin, Baycol, Lipobay, cholestyramine, Cholestyramine Resin, Colestyramin, Colestyramins, Colestyramine, Colestyramines, Cholestyramine, Cholestyramines, Questran, Questrans, Quantalan, Quantalans, Cuemid, Cuemids, MK-135, MK 135, MK135, , clarithromycin, clopidogrel, Plavix, Iscover, colestipol, Colestipol, Colestipol Hydrochloride, Colestipol HCl, Colestid, , coumadin, dabigatran, Pradaxa, Pradax, hydralazine, Hydralazine, Hydralazin, Hydrazinophthalazine, Apressin, Nepresol, Hydralazine mono-Hydrochloride, Hydralazine mono Hydrochloride, Apressoline, Apresoline, Hydralazine Hydrochloride, , idraparinux, idraparinux, , iloprost, indapamide, irbesartan, Aprovel, Avapro, Karvea, isradipine, ivabradine, ivabradine, Corlanor, Procorolan, S 16257-2, S-16257-2, S-16260-2, S 16260-2, S 16257, S-16257, , lanoteplase, SUN 9216, SUN9216, SUN-9216, lanoteplase, , lidocaine, lisinopril, Lisinopril, Lysinopril, Zestril, Prinivil, MK-521, , losartan, Losartan, Cozaar, MK-954, MK 954, MK954, DuP-753, DuP 753, DuP753, Losartan Potassium, Losartan Monopotassium Salt, , lovastatin, Lovastatin, Mevinolin, Monacolin K, 6-Methylcompactin, 6 Methylcompactin, MK-803, MK 803, MK803, Mevacor, , metoprolol, Metoprolol, Beloc-Duriles, Beloc Duriles, BelocDuriles, Betalok, Spesicor, Spesikor, H 93-26, H 93 26, H 9326, Lopressor, Metoprolol Tartrate, Seloken, Betaloc, Betaloc-Astra, Betaloc Astra, BetalocAstra, CGP-2175, CGP 2175, CGP2175, , naftidrofuryl, nebivolol, nebivolol, nebivolol hydrochloride, Silostar, Nebilet, Lobivon, R 67555, R-67555, , niacin, Niacin, Nicotinic Acid, 3-Pyridinecarboxylic Acid, 3 Pyridinecarboxylic Acid, Induracin, Nicamin, Nico-400, Nico 400, Nico400, Nicobid, Nicocap, Nicolar, Nicotinate, Wampocap, Enduracin, Lithium Nicotinate, angioplasty, APSAC, ardeparin, argatroban, captopril, SQ-14534, SQ 14534, SQ14534, SQ-14225, SQ 14225, SQ14225, Capoten, Lopirin, , dipyridamol, dipyridamole monoacetate, dipyridamol monoacetate, , digoxin, Digoxin, Digacin, Digitek, Digoregen, Lanoxin, Lanoxin-PG, Lanoxin PG, Lenoxin, Digoxine Nativelle, Hemigoxine Nativelle, Dilanacin, Lanacordin, Lanicor, Lanoxicaps, Mapluxin, Digoxina Boehringer, , diltiazem, diet, dicoumarol, Dicoumarol, Dicoumarol, Bishydroxycoumarin, Dicoumarin, , drug-eluting stents, CYPHER, TAXUS, Promus, Xience, Biomatrix, Nobori, Endeavor, Drug-Eluting Stents, Drug Eluting Stents, Drug-Eluting Stent, Drug-Coated Stents, Drug Coated Stents, Drug-Coated Stent, , dronedarone, Multaq, enalapril, ezetimibe, Zetia, Ezetrol, felodipine, Felodipine, Felo Biochemie, Felo-Puren, Felo Puren, Felobeta, Felocor, Felodipin 1A Pharma, Felodipin AbZ, Felodipin AL, Felodipin AZU, Felodipin dura, Felodur, Felogamma, Fensel, H 154-82, H 154 82, H 15482, Plendil, Flodil, Modip, Renedil, Munobal, Felodipin Heumann, Felodipin Stada, felodipin von ct, Felodipin-ratiopharm, Felodipin ratiopharm, Perfudal, Agon, , fenofibrate, Procetofen, flecainide, Flecainide, Flecatab, Flecainide Acetate, Flecainide Monoacetate, R818, Tambocor, Apocard, Flcane, Flecadura, Flecainid-Isis, Flecainid Isis, , fish oil, Fish Oils, Fish Liver Oils, , fluvastatin, fluvastatin, fluindostatin, Lescol, XU 62-320, XU-62320, XU 62320, fluvastatin sodium, fluvastatin sodium salt, , fondaparinux, Quixidar, Arixtra, fosinopril, Fosinopril, Fosenopril, Monopril, Staril, Fosinorm, Newace, Hiperlex, Fozitec, Fosinil, Fositens, Dynacil, Tenso Stop, Tensocardil, Fosinopril Sodium, SQ-28555, SQ 28555, SQ28555, , fraxiparin, Nadroparin, Nadroparine, Nadroparin Calcium, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216, , furosemide, Furosemide, Frusemide, Fursemide, Frusemid, Furanthril, Furantral, Salix (brand of furosemide), Furosemide Monosodium Salt, Fusid, Lasix, Errolon, Furosemide Monohydrochloride, , gemfibrozil, Gemfibrozil, Gemfibrosil, Bolutol, CI-719, CI 719, CI719, DBL Gemfibrozil, Trialmin, Decrelip, Gemfi 1A Pharma, Gemfibrozilo Ur, Gemhexal, Gen-Gemfibrozil, Gen Gemfibrozil, GenGemfibrozil, GenRX Gemfibrozil, Healthsense Gemfibrozil, Jezil, Lipazil, Lipox Gemfi, Litarek, Lopid, Lopid R, Lipur, Pilder, SBPA Gemfibrozil, Apo-Gemfibrozil, Apo Gemfibrozil, ApoGemfibrozil, Ausgem, , heparin, Heparin, Unfractionated Heparin, Heparinic Acid, Liquaemin, Sodium Heparin, Heparin Sodium, alpha-Heparin, alpha Heparin, , hirudin, ibopamine, labetalol, Labetalol, Labetolol, Albetol, Apo-Labetalol, Apo Labetalol, ApoLabetalol, Dilevalol, Normodyne, Presolol, SCH-19927, SCH 19927, SCH19927, Trandate, AH-5158, AH 5158, AH5158, Labetalol Hydrochloride, , magnesium, nadroparin, Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216,

LMF CY-216, LMF CY 216, LMF CY216, , nicardipine, Nicardipine, Cardene SR, Dagan, Flusemide, Lecibral, Lincil, Loxen, Lucenfal, Nicardipine Hydrochloride, Nicardipine LA, Nicardipino Ratiopharm, Nicardipino Seid, Perdipine, Ridene, Y-93, Y 93, Y93, Cardene I.V., Cardene, Vasonase, Antagonil, , nicorandil, Nicorandil, 2-Nicotinamidoethyl Nitrate, 2 Nicotinamidoethyl Nitrate, 2-Nicotinamidethyl Nitrate, 2 Nicotinamidethyl Nitrate, SG-75, SG 75, SG75, Ikorel, Adancor, Dancor, , nifedipine, nifedipine, Nifedipine, Adalat, Bay-1040, Bay 1040, Bay1040, BAY-a-1040, BAY a 1040, BAYa1040, Procardia XL, Nifedipine-GTIS, Nifedipine GTIS, Corinfar, Korinfar, Fenigidin, Nifangin, Nifedipine Monohydrochloride, Procardia, Vascard, Cordipin, Cordipine, , nitroglycerin, Nitroglycerin, Glyceryl Trinitrate, Nitrolan, Nitrostat, Perlinganit, Susadrin, Sustac, Sustak, Sustonit, Transderm Nitro, Tridil, Trinitrin, Trinitrolong, Anginine, Dynamite, Gilustenon, Nitrangin, Nitro-Bid, Nitro Bid, NitroBid, Nitro-Dur, Nitro Dur, NitroDur, Nitrocard, Nitroderm, Nitroderm TTS, Nitroglyn, Nitrol, Nitrong, Nitrospan, , omapatrilat, omapatrilat, Vanlev, BMS 186716, BMS-186716, , omacor, Omacor, Lovaza, omega-3 ethyl ester 90, P-OM3 adjunct, , dalteparin, logiparin, Logiparin, LHN-1, , orlistat, orlistat, tetrahydrolipstatin, THLP, Alli, Xenical, , oxprenolol, pentoxifylline, Pentoxifylline, Oxpentifylline, BL-191, BL 191, BL191, Trental, Torental, Agapurin, Pentoxil, , perindopril, Perindopril, Pirindopril, Perstarium, S-9490, S 9490, S9490, S 9490-3, S 9490 3, S 94903, Perindopril Erbumine, , pindolol, picotamide, pioglitazone, Actos, practolol, Practolol, ICI-50172, ICI 50172, ICI50172, Dalzic, Eralzdin Practolol, , pravastatin, Pravastatin, Eptastatin, Liplat, RMS-431, RMS 431, RMS431, SQ-31000, SQ 31000, SQ31000, Vasten, Bristacol, CS-514, CS 514, CS514, Lipemol, Prareduct, Mevalotin, Pravachol, Elisor, Selektine, Pravacol, Pravasin, Lipostat, , prasugrel, prasugrel, CS 747, CS-747, LY 640315, LY640315, LY-640315, Effient, Efient, PCI, probucol, Probuco, DH-581, DH 581, DH581, Lorelco, Lurselle, Superlipid, Biphenabid, Panavir, , propranolol, Propranolol, Propanolol, Avlocardyl, AY-20694, AY 20694, AY20694, Betadren, Dexpropranolol, Inderal, Obsidan, Obzidan, Propranolol Hydrochloride, Rexion, Anaprilin, Anapriline, Dociton, , propranolol, quinapril, quinidine, ramipril, Triatec, Altace, Delix, Ramace, Vesdil, Carasel, Acovil, Tritace, Zabien, ranolazine, renolazine, RS 43285-193, Ranexa, RS 43285, RS-43285, , rimonabant, rimonabant, SR141716, SR 141716, Acomplia, Zimulti, SR 141716A, SR141716A, SR-141716A, , risedronate, rivaroxaban, Xarelto, BAY 59-7939, , rosiglitazone, Avandia, rosuvastatin, Crestor, rt-PA, Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , saruplase, saruplase, prourokinase (enzyme-activating), recombinant unglycosylated single-chain urokinase-type plasminogen activator, pro-urokinase, Rescupase, A-74187, , simvastatin, Zocor, sotalol, Darob, MJ-1999, MJ 1999, MJ1999, , streptokinase, sulfinpyrazone, suloctidil, sulotroban, t-pa, telmisartan, telmisartan, Micardis, BIBR 277, BIBR-277, Pritor, , tenecteplase, tenecteplase, Metalyse, TNKase, terbogrel, ticlopidine, Ticlopidine, Ticlopidine Hydrochloride, Ticlodix, Ticlodone, 53-32C, 53 32C, 5332C, Ticlid, , timolol, Timolol, Timoptic, Timoptol, Timolol Hemihydrate, Timacar, Timolol Maleate, MK-950, MK 950, MK950, Optimol, Blocadren, , tinzaparin, tinzaparin, tinzaparin sodium, Innohep, tirofiban, tirofiban, tirofiban hydrochloride monohydrate, MK 383, MK-383, tirofiban hydrochloride, Aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp and Dohme brand of tirofiban hydrochloride monohydrate, Agravastat, Merck brand of tirofiban hydrochloride monohydrate, L 700462, L-700462, , tolvaptan, tolvaptan, OPC 41061, OPC-41061, Samsca, , topiramate, topiramate, Topamax, Epitomax, McN 4853, McN-4853, , trandolapril, trandolapril, Odrik, Udrik, RU 44570, RU44570, RU-44570, Mavik, Gopten, triflusal, triflusal, Disgren, trimetazidine, Centrophne, Vastarel, Idaptan, Trintazidine Irex, Vasartel, Trimetazidine Dihydrochloride, , urokinase, Urokinase-Type Plasminogen Activator, Urokinase Type Plasminogen Activator, U-Plasminogen Activator, U Plasminogen Activator, U-PA, Urinary Plasminogen Activator, Urokinase, Renokinase, Abbokinase, Kidney Plasminogen Activator, Single-Chain Urokinase-Type Plasminogen Activator, Single Chain Urokinase Type Plasminogen Activator, , valsartan, valsartan, Diovan, Tareg, KalpressMiten, Provas, Vals, walsartan, CGP 48933, Nisis, Aventis brand of valsartan, , verapamil, Verapamil, Iproveratril, Cordilox, Dexverapamil, Falicard, Izoptin, Isoptine, Isoptin, Lekoptin, Verapamil Hydrochloride, Calan, Finoptin, , vesnarinone, vesnarinone, OPC 8212, OPC-8212, , vitamin c, vitamin e, warfarin, xamoterol, Xamoterol, Corwin, ICI-118587, ICI 118587, ICI118587, Xamoterol Fumarate, Xamoterol Hemifumarate, Xamoterol Monohydrobromide, Xamoterol Monohydrochloride, Xamtol, Carwin, Xamoterol Maleate (2:1), , ximelagatran, ximelagatran, xi-melagatran, Exanta, H 376 95, H 376-95, , glipizide, Glucotrol, wafarin, Warfarin, Coumadin, Apo-Warfarin, Gen-Warfarin, Warfant, Coumadin, Marevan, Warfarin Potassium, Warfarin Sodium, Aldocumar, Tedicumar, , UFH, thiazid diuretic, sulodexide, reviparin, reviparin, reviparine, reviparin-sodium, reviparin sodium, LU 47311, LU-47311, Clivarin, Abbott brand of reviparin-sodium, Clivarine, ICN brand of reviparin-sodium, , propafenone, Propafenone, Propamerck, Rythmol, Arythmol, Rytmonorm, Norfenon, Pintoform, Propafenon Minden, Rytmo-Puren, Rytmogenat, Baxarytmon, Cuxafenon, Fenoprain, Jutanorm, Nistaken, Prolecufen, ,, nateglinide, nateglinide, nate-glinide, senaglinide, IPCCPA, AY 4166, AY-4166, DJN 608, Starsis,

Starlix, Novartis brand of nateglinide, A 4166, A-4166, Fastic, , nisoldipine, Bay K 5552, , metformin, Metformin, Dimethylguanylguanidine, Dimethylbiguanidine, Glucophage, , glyburide, Glyburide, Glybenclamide, Glibenclamide, Diabeta, Euglucon 5, Neogluconin, HB-419, HB 419, HB419, HB-420, HB 420, HB420, Maninil, Micronase, Daonil, Euglucon N, , 4-transhydroxy glyburide, , Glucovance, Glyburide-metformin, , eptifibatide, Integrilin, Integrelin, PTCA, reteplase, reteplase, Retavase, Rapilysin, betaxolol, Betaxolol, SL-75212, SL 75212, SL75212, Betoptic, Betoptima, Betaxolol, Oxodal, ALO-1401-02, ALO 1401 02, ALO140102, Betaxolol, atorvastatin, Lipitor, anistreplase, estrogen, thyroxine, policosanol, hydralazine-ISDN, isosorbide dinitrate, pactimibe, epoprostenol, torcetrapib, torcetrapib, CP 529414, CP529414, CP-529414, , catheter ablation, sirolimus eluting stent, CYPHER, , biolimus eluting stent, everolimus eluting stent, XIENCE V, Guidant XIENCE V, Abbott XIENCE V, XIENCE 5, zotarolimus eluting stent, Endeavour, Medtronic Endeavour, albiglutide, albiglutide, , ketanserine, liraglutide, liraglutide, victoza, nouveau, exenatide, exendin 4, exendin-4, Ex4 peptide, Byetta, AC 2993, AC 2993 LAR, , sitagliptin, sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431, , amlodipine, abciximab, acenocoumarol, Acenocoumarol, Nicoumalone, Acenocoumarin, Synthrome, Synthrom, Syncoumar, Syncumar, Sinkumar, Sintrom, Mini-Sintrom, Mini Sintrom, MiniSintrom, , alteplase, Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , beta carotene, bepridil, Bepridil Monohydrochloride, Vascor, Bedapin, CERM-1978, CERM 1978, CERM1978, 1978-CERM, 1978 CERM, 1978CERM, Cordium, Unicordium, Bepadin, , clofibrate, Ethyl Chlorophenoxyisobutyrate, Atromid, Atromid S, Miscleron, Miskleron, Athromidin, , elinogrel, elinogrel, PRT 060128, PRT060128, PRT-060128, , nesiritide, Brain Natriuretic Peptide, BNP-32, BNP 32, Nesiritide, B-Type Natriuretic Peptide, BNP Gene Product, Type-B Natriuretic Peptide, Type B Natriuretic Peptide, Natriuretic Peptide Type-B, Natriuretic Peptide Type B, Natriuretic Factor-32, Natriuretic Factor 32, Brain Natriuretic Peptide-32, Brain Natriuretic Peptide 32, Natrecor, , phenindione, Phenindione, Phenylindanedione, Phenylene, Pindione, Fenilin, Dindevan, , repaglinide, repa-glinide, AG-EE 388 ZW, NovoNorm, GlucoNorm, Prandin, AG-EE 388, AG-EE 623 ZW, , ticagrelor, Brilique, Brilinta, AZD 6140, AZD6140, AZD-6140, zofenopril, zofenopril, Zofenil, Zofil, SQ 26900, SQ-26900, SQ 26991, SQ-26991, , SQ 26703, zofenopril-SH, zofenopril-SH cpd with arginine, , anacetrapib, MK 0859, MK0859, MK-0859, , atopaxar, betrixaban, PRT054021, , buflomedil, blufomedil, bufomedil, Buflo AbZ, AbZ brand of buflomedil hydrochloride, Buflo-POS, Ursapharm brand of buflomedil hydrochloride, Buflo-Puren, Alpharma brand of buflomedil hydrochloride, Buflohexal, Hexal brand of buflomedil hydrochloride, Buflomedil Heumann, Heumann brand of buflomedil hydrochloride, buflomedil hydrochloride, Buflomedil Lindo, Lindopharm brand of buflomedil hydrochloride, buflomedil pyridoxal phosphate, Buflomedil Stada, Stadapharm brand of buflomedil hydrochloride, buflomedil von ct, ct-Arzneimittel brand of buflomedil hydrochloride, Buflomedil-ratiopharm, ratiopharm brand of buflomedil hydrochloride, Fonzylane, Lafon brand of buflomedil hydrochloride, LL 1656, Loftyl, Bufedil, Lofton, Abbott brand of buflomedil hydrochloride, Sinoxis, Hosbon brand of buflomedil hydrochloride, Buflo 1A Pharma, 1A brand of buflomedil hydrochloride, , folic acid, Folic Acid, Vitamin M, Pteroylglutamic Acid, Folate, Folvite, Folacin, , hydrochlorothiazide, Hydrochlorothiazide, HCTZ, Dichlothiazide, Dihydrochlorothiazide, HydroDIURIL, Oretic, Sectrazide, Esidrix, Esidrex, Hypothiazide, , inogatran, inogatran, N-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidinyl)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine, H 314-27, H314-27, H-314-27, , troglitazone, voglibose, voglibose, Basen, , trapidil, Trapidil, Trapymine, Rocornal, , desdiethyltrapidil, N-dediethyltrapidil, desdiethyltrapidil, , Certoparin, certoparin, certoparin sodium, Mono-Embolex, Novartis brand of certoparin sodium, Alphaparin, Grifols brand of certoparin sodium, , glimepiride, glimepiride, glymepiride, HOE 490, HOE-490, Roname, Amaryl, Amarel, hydroxyglimepiride, hydroxy-glimepiride, , linagliptin, Linagliptin, Tradjenta, BI 1356, BI1356, BI-1356, , taspoglutide, taspoglutide, , mitiglinide, miti-glinide, KAD 1229, KAD-1229, , TAVI, transcatheter aortic valve implantation, , Sibutramine, sibutramine, Meridia, mono-desmethylsibutramine, BTS 54 524, BTS-54524, BTS 54524, Reductil, di-desmethylsibutramine, didesmethylsibutramine, (R)-DDMS, sibutramine hydrochloride, , saxagliptin, saxagliptin, Onglyza, BMS 477118, BMS477118, BMS-477118, , divers, edoxaban, eplerenone, eplerenon, Inspra, fibroblast growth factor, aliskiren, CGP 060536B, CGP060536B, CGP-060536B, Tekturna, SPP100, , alogliptin, SYR 322, SYR322, SYR-322, , Azithromycin, benfluorex, benfluramate, benfluorex maleate, SE 780, 780 SE, JP 992, Mediator trade name of benfluorex hydrochloride, Biopharma brand of benfluorex hydrochloride, Modulator trade name of benfluorex hydrochloride, Servier brand of benfluorex hydrochloride, S 780, benfluorex hydrochloride, 1-(2-trifluoromethylphenyl)-2-(benzoyloxyethyl)aminopropane HCl, , bosentan, Coronary Artery Bypass Surgery, Coronary Artery Bypass, Coronary Artery Bypasses, Coronary Artery Bypass Surgery, Aortocoronary Bypass, Aortocoronary Bypasses, Coronary Artery Bypass Grafting, CABG, cangrelor, AR C69931MX, AR-C69931MX, , caval filter, carotid endarterectomy, Carotid Endarterectomy, Carotid Endarterectomies, , carotid artery stenting, cilostazol, chlorthalidone, Chlortalidone, Phthalamudine, Chlorphthalidolone, Oxodoline, Thalitone, Hygroton, , dactinomycin eluting stent, defi-

brotide, disopyramide, dofetilide, dofetilide, 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane, 1-MSPMPE, Tikosyn, UK 68798, , docetaxel, docetaxol, Taxoltere metro, Taxotere, NSC 628503, RP 56976, RP-56976, Ebselen, ebselen, PZ 51, PZ-51, RP 60931, DR 3305, DR-3305, , Enoximone, Fenoximone, Perfan, MDL 19438, MDL-17043, MDL 17043, MDL17043, , enoximone sulfoxide, MDL 17043 sulfoxide, , Exercise Therapy, Exercise Therapy, Exercise Therapies, , Flosequinan, gene therapy, Gene Therapy, DNA Therapy, Somatic Gene Therapy, , ginko biloba, Ginkgo biloba, Ginkgo bilobas, Ginko, Ginkos, Ginkgo, Ginkgos, Gingko, Gingkos, Maidenhair Tree, Maidenhair Trees, Gingko biloba, Gingko bilobas, Ginkgophyta, Ginkgophytas, , lacidipine, Lacipil, Lacimen, Caldine, Motens, GR 43659X, GR-43659X, , molsidomine, mibefradil, lorcaserin, olmesartan, olmesartan medoxomil, CS 866, CS-866, Votum, Benicar, Olmetec, , nimodipine, Nimesulide, moricizine, otamixaban, pexelizumab, h5G1.1-scFv, pexelizumab, , Ambrisentan, amitriptyline, Azimilide, Bemiparin, Bupropion, Celecoxib, cilazapril, deltaparin, Dalteparin, Tedelparin, Kabi-2165, Kabi 2165, Kabi2165, Fragmin, Fragmine, Dalteparin Sodium, FR-860, FR 860, FR860, , Diazepam, Diclofenac, Efeqatran, efeqatran, Me-Phe-Pro-Arg-H, D-methyl-phenylalanyl-prolyl-arginal, GYKI 14766, GYKI-14766, LY 294468, LY-294468, efeqatran sulfate, , Enlimomab, etofibrate, etofibrate, Lipo-Merz, Merz brand of etofibrate, Tricerol, Armstrong brand of etofibrate, etofibrate hydrochloride, , levosimendan, simendan, OR-1855, Simadax, dextrosimendan, OR 1259, OR-1259, , Milrinone, lixisenatide , ZP10A peptide, AVE 0010, AVE0010, AVE-0010, Lixisenatide, AQVE-10010, , primary angioplasty, primary ballon angioplasty, primary PTCA, vildagliptin, vildagliptin, (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, NVP-LAF237, Galvus, , gliclazide, Gliclazide, Glyclazide, Gliklazid, Diamicon, S-1702, S 1702, S1702, S-852, S 852, S852, Diaglyk, Gen-Gliclazide, Gen Gliclazide, Glyade, Novo-Gliclazide, Novo Gliclazide, Diaikron, Diabrezide, , phentermine and topiramate, Qnexa, glimepiride, glargine, vorapaxar, Zontivity, SCH 530348, SCH530348, SCH-530348, , nivolumab, MDX-1106, ONO-4538, BMS-936558, Opdivo, pembrolizumab, lambrolizumab, Keytruda, MK-3475, , ipilimumab, MDX-CTLA-4, Yervoy, DX 010, MDX010, MDX-010, , gefitinib, Iressa, ZD1839, ZD 1839, , paclitaxel, Anzatax, NSC-125973, NSC 125973, NSC125973, Taxol, Taxol A, Bris Taxol, Paxene, Praxel, 7-epi-Taxol, 7 epi Taxol, Onxol, everolimus, SDZ RAD, SDZ-RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD 001, RAD001, Afinitor, Certican, , pertuzumab, pertuzumab, Perjeta, Omnitarg, trastuzumab emtansine , ado-trastuzumab emtansine, trastuzumab-DM1, trastuzumab-DM1 conjugate, T-DM1 cpd, trastuzumab emtansine, huN901-DM1, Kadcylla, lapatinib , bevacizumab, Avastin, , gemcitabine, gemcitabine, dFdCyd, 2'-deoxy-2'-difluorocytidine, gemcitabine hydrochloride, LY 188011, LY-188011, Gemzar, , toremifene , Toremifene, Toremifene Citrate, Toremifene Citrate (1:1), Fareston, FC-1157a, FC 1157a, FC1157a, , capecitabine , Xeloda, , cisplatin , Cisplatin, cis-Diamminedichloroplatinum(II), Platinum Diamminodichloride, cis-Platinum, cis Platinum, Dichlorodiammineplatinum, cis-Diamminedichloroplatinum, cis Diamminedichloroplatinum, cis-Dichlorodiammineplatinum(II), NSC-119875, Platino, Platinol, Biocisplatinum, Platidiam, , fulvestrant , ICI 182780, ICI-182780, ZM 182780, ZM-182780, Faslodex, , palbociclib , palbociclib, Ibrance, PD 0332991, PD0332991, PD-0332991, anastrozole, anastrozole, anastrazole, ICI D1033, ZD-1033, Zeneca ZD 1033, ZD1033, Arimidex, letrozole, letrozole, Femara, Fmara, CGS 20267, CGS-20267, aminoglutethimide , Aminoglutethimide, Cytadren, Orimeten, formestane , formestane, 4-hydroxyandrostenedione, 4-OHA, Lentaron, CGP-32349, CGP 32 349, CGP 32349, , exemestane , exemestane, FCE 24304, FCE-24304, Aromasil, Aromasin, Aromasine, , fadrozole , Fadrozole, CGS-16949A, CGS 16949A, CGS16949A, Fadrozole Hydrochloride, Fadrozole Monohydrochloride, CGS 020286A, CGS020286A, CGS-020286A, FAD 286, FAD286, FAD-286, , tamoxifen, Tamoxifen, ICI-47699, ICI 47699, ICI47699, Nolvadex, Novaldex, Tamoxifen Citrate, Tomaxithen, Zitazonium, ICI-46474, ICI 46474, ICI46474, Soltamox, ixabepilone , ixabepilone, BMS247550, BMS-247550, BMS 247550, trastuzumab, Herceptin, temsirolimus , Torisel, CCI 779, CCI-779, , alirocumab, alirocumab, REGN727 monoclonal antibody, monoclonal antibody REGN727, SAR236553, Praluent, , evolocumab , AMG 145, evolocumab, AMG-145, Repatha, medroxyprogesterone , Medroxyprogesterone Acetate, Medroxyprogesterone 17-Acetate, Medroxyprogesterone 17 Acetate, Depo-Medroxyprogesterone Acetate, Depo Medroxyprogesterone Acetate, 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate, 6 alpha Methyl 17alpha hydroxyprogesterone Acetate, Curretab, Cycrin, Depo-Provera, Depo Provera, DepoProvera, Farlutal, Perlutex, Provera, Veramix, Clinovir, Gestapuran, sorafenib, sorafenib, sorafenib N-oxide, 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methamide-4-methylbenzenesulfonate, BAY 545-9085, BAY-545-9085, sorafenib tosylate, BAY 43-9006, Nexavar, , entinostat , entinostat, SNDX-275, MS 27-275, MS-275, MS 275, MS-27-275, eribulin, B 1939, B-1939, E 7389, E-7389, Halaven, NSC 707389, NSC707389, NSC-707389, B 1793, B-1793, ER-086526, ER086526, ER 086526, ER-86526, , nab-paclitaxel, Abraxane, vinorelbine , vinorelbine, 5'-nor-anhydrovinblastine, Navelbine, vinorelbine tartrate, KW 2307, KW-2307, , intensive blood pressure lowering strategies, intensive treatment, tighter control of blood pressure, low target blood pressure, strict blood pressure control, intensified blood-pressure control, cetuximab, IMC C225, IMC-C225, MAb C225, C225, Erbitux, , erlotinib, Tarceva, CP 358774, CP-358774, OSI-774, axitinib, Inlyta, AG 013736, AG013736, AG-013736, , dovitinib, TKI 258, TKI258, TKI-258, dovitinib, CHIR 258, CHIR258, CHIR-258, , pazopanib,

GW 786034B, GW786034B, GW-786034B, GW 780604, GW780604, GW-780604, Votrient, , sunitinib, Sutent, SU 11248, SU11248, SU-11248, SU011248, SU 011248, SU-011248, , adalimumab , D2E7 Antibody, Humira, certolizumab, Cimzia, Cimzias, CDP870, CDP870s, CDP 870, CDP 870s, , etanercept , TNF Receptor Type II-IgG Fusion Protein, TNF Receptor Type II IgG Fusion Protein, Enbrel, Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein, Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein, TNFR-Fc Fusion Protein, TNFR Fc Fusion Protein, TNR-001, TNR001, TNR 001, TNT Receptor Fusion Protein, TNTR-Fc, , golimumab , Simponi, , infliximab , MAb cA2, Monoclonal Antibody cA2, Remicade, , anakinra , Interleukin 1 Receptor Antagonist Protein, Urine-Derived IL1 Inhibitor, Urine Derived IL1 Inhibitor, IL1 Febrile Inhibitor, Urine IL-1 Inhibitor, IL-1Ra, Anril, Kineret, Anakinra, , tocilizumab , tocilizumab, atlizumab, Actemra, , rituximab, Rituxan, MabThera, Zytux, Rituximab, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, IDEC C2B8 Antibody, IDECC2B8 Antibody, IDEC-C2B8, IDEC C2B8, IDECC2B8, GP2013, Rituxan, , tofacitinib, tasocitinib, tofacitinib citrate, Xeljanz, CP690550, CP-690550, CP 690550, , durvalumab, durvalumab, Imfinzi, atezolizumab, MPDL3280A, Tecentriq, RG7446, RG-7446, , pemetrexed , MTA, Pemetrexed Disodium, LY 231514, LY231514, LY-231514, Alimta, , rolofylline , rolofylline, KW 3902, KW-3902, MK 7418, MK7418, MK-7418, , tonapofylline , BG 9928, BG-9928, BG9928, BIO 4683, BIO4683, BIO-4683, BIO 5770, BIO5770, BIO-5770, BIO 8170, BIO8170, BIO-8170, BIO 9002, BIO9002, BIO-9002, tonapofylline, BIO 7505, BIO7505, BIO-7505, , serelaxin, canagliflozin, Invokana, , empagliflozin, BI 10773, BI10773, BI-10773, Jardiance, , dapagliflozin, dapagliflozin, forxiga, BMS 512148, BMS512148, BMS-512148, , avelumab , avelumab, MSB0010718C, , crizotinib , Xalkori, PF-02341066, PF02341066, PF 02341066, , finerenone, BAY 94-8862, finerenone, , olaparib, AZD 2281, AZD2281, AZD-2281, AZD221, Lynparza, , niraparib , 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide, niraparib hydrochloride, MK 4827, MK4827, MK-4827, , talazoparib , BMN 673, , veliparib , 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, 2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, ABT 888, ABT888, ABT-888, , bococizumab, bococizumab, , various diuretics, various ACEI, various beta blockers, alectinib, CH5424802, alectinib, RO5424802, , ceritinib, ceritinib, Zykadia, LDK378, , brigatinib, AP26113, brigatinib, , vandetanib , caprelsa, ZD 6474, ZD6474, ZD-6474, vandetanib, Zactima, , motesanib , imetelstat, motesanib, motesanib diphosphate, AMG 706, AMG706, AMG-706, , aflibercept , aflibercept, VEGF Trap-Eye, VEGF Trap - regeneron, VEGF-Trap, AVE 005, AVE005, AVE-005, Zaltrap, ZIV-aflibercept, AVE 0005, AVE0005, AVE-0005, eylea, , osimertinib , osimertinib, Tagrisso, , rucaparib, rucaparib, AG 014699, AG014699, AG-014699, PF-01367338, , various, cabozantinib , cabozantinib, Cometriq, XL 184, XL184 cpd, XL-184, BMS 907351, BMS907351, BMS-907351, , apitolisib , tivozanib , abemaciclib , abemaciclib, LY2835210, LY2385219, Verzenio, ribociclib , ribociclib, LEE011, , vemurafenib, vemurafenib, Zelboraf, R05185426, RG7204, RG-7204, PLX4032, PLX 4032, , combo dabrafenib + trametinib, durvalumab + tremelimumab , ticilimumab, CP 675, P675 cpd, CP-675, CP-675,206, CP-675206, CP675206, CP 675206,

## 10 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.